dovitinib

A benzimidazole-quinolinone compound and receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Dovitinib binds to and… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Dovitinib is an oral multikinase inhibitor targeting FGF receptors, PDGF receptors and VEGF receptors. Its activity against FGF… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2015
2015
BACKGROUND Activating FGFR2 mutations are found in 10-16% of primary endometrial cancers and provide an opportunity for targeted… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2014
2014
Bone is the most common site of prostate cancer (PCa) progression to a therapy-resistant, lethal phenotype. We found that… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2013
Highly Cited
2013
PURPOSE Fibroblast growth factor receptor 1 (FGFR1) and FGFR2 amplifications are observed in approximately 10% of breast cancers… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
2013
2013
PURPOSE Signaling through the fibroblast growth factor (FGF) pathway may account for tumor resistance to antiangiogenic therapies… (More)
Is this relevant?
2013
2013
The recent identification of activating fibroblast growth factor receptor 2 (FGFR2) mutations in endometrial cancer has generated… (More)
Is this relevant?
2013
2013
Dovitinib is an oral multitargeted kinase inhibitor with potent activity against receptors for vascular endothelial growth factor… (More)
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Most anticancer drugs entering clinical trials fail to achieve approval from the U.S. Food and Drug Administration. Drug… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2012
Highly Cited
2012
The multiple kinase inhibitor dovitinib is currently under clinical investigation for hepatocellular carcinoma (HCC). Here, we… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2011
2011
PURPOSE Dovitinib (TKI258) is an orally available inhibitor of fibroblast growth factor (FGF), VEGF, and platelet-derived growth… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?